Standard Prophylactic Enoxaparin Dosing Leads to Inadequate Anti-Xa Levels and Increased Deep Venous Thrombosis Rates in Critically Ill Trauma and Surgical Patients
- 1 April 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Journal of Trauma and Acute Care Surgery
- Vol. 68 (4), 874-880
- https://doi.org/10.1097/ta.0b013e3181d32271
Abstract
Deep venous thromboses (DVT) continue to cause significant morbidity in critically ill patients. Standard prophylaxis for high risk patients includes twice-daily dosing with 30 mg enoxaparin. Despite prophylaxis, DVT rates still exceed 10% to 15%. Anti-Xa levels are used to measure the activity of enoxaparin and 12-hour trough levels <or=0.1 IU/mL have been associated with higher rates of DVT in orthopedic patients. We hypothesized that low Anti-Xa levels would be found in critically ill trauma and surgical patients and that low levels would be associated with higher rates of DVT. All patients on the surgical intensive care unit (ICU) service were prospectively followed. In the absence of contraindications, patients were given prophylactic enoxaparin and anti-Xa levels were drawn after the third dose. Trough levels <or=0.1 IU/mL were considered low. Screening duplex exams were obtained within 48 hours of admission and then weekly. Patients were excluded if they did not receive a duplex, if they had a prior DVT, or if they lacked correctly timed anti-Xa levels. DVT rates and demographic data were compared between patients with low and normal anti-Xa levels. Data were complete for 54 patients. Eighty-five percent suffered trauma (Injury Severity Score of 25 +/- 12) and 74% were male. Overall, 27 patients (50%) had low anti-Xa levels. Patients with low anti-Xa levels had significantly more DVTs than those with normal levels (37% vs. 11%, p = 0.026), despite similar age, body mass index, Injury Severity Score, creatinine clearance, high risk injuries, and ICU/ventilator days. Standard dosing of enoxaparin leads to low anti-Xa levels in half of surgical ICU patients. Low levels are associated with a significant increase in the risk of DVT. These data support future studies using adjusted-dose enoxaparin.Keywords
This publication has 22 references indexed in Scilit:
- La actividad anti-Xa depende del peso en pacientes médicos que reciben tromboprofilaxis con enoxaparinaArchivos de Bronconeumología, 2008
- Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?*Critical Care Medicine, 2003
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparinThrombosis Research, 2002
- Inability of an aggressive policy of thromboprophylaxis to prevent deep venous thrombosis (dvt) in critically injured patients: are current methods of dvt prophylaxis insufficient?Journal of the American College of Surgeons, 1998
- Posttrauma Thromboembolism ProphylaxisThe Journal of Trauma and Acute Care Surgery, 1997
- A Comparison of Low-Dose Heparin with Low-Molecular-Weight Heparin as Prophylaxis against Venous Thromboembolism after Major TraumaThe New England Journal of Medicine, 1996
- A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgeryThe American Journal of Surgery, 1995
- A Prospective Study of Venous Thromboembolism after Major TraumaThe New England Journal of Medicine, 1994
- Adjusted versus Fixed-Dose Subcutaneous Heparin in the Prevention of Deep-Vein Thrombosis after Total Hip ReplacementThe New England Journal of Medicine, 1983